Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States

被引:9
|
作者
Michailidou, Despina [1 ,2 ]
Zhang, Tianyu [3 ]
Stamatis, Pavlos [4 ]
Ng, Bernard [1 ,2 ]
机构
[1] Univ Washington, Dept Med, Div Rheumatol, 1959 Pacific St, Seattle, WA 98195 USA
[2] VA Puget Sound Healthcare Syst, Rheumatol Sect, Seattle, WA USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[4] Lund Univ, Dept Clin Sci Lund, Rheumatol, Lund, Sweden
关键词
central retinal artery occlusion; central retinal venous occlusion; giant cell arteritis; osteoarthritis; polymyalgia rheumatica; thromboembolism; CHARLSON COMORBIDITY INDEX; PULMONARY-EMBOLISM; ISCHEMIC COMPLICATIONS; EPIDEMIOLOGY; PREVALENCE; SPECTRUM; DISEASE; TRENDS; SERIES;
D O I
10.1111/joim.13446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are systemic inflammatory diseases that primarily affect elderly women. Objectives To compare the risk of thromboembolic events and retinal vascular occlusions in GCA and/or PMR with that in osteoarthritis (OA), evaluating a veteran-based population. Methods A total of 1535 patients with GCA, 10,265 with PMR, and 1203 with overlapping disease, as well as 39,009 age- and sex-matched patients with OA were identified in this retrospective study. The incidence rate ratios (IRRs) of pulmonary embolism (PE), deep venous thrombosis (DVT), arterial thromboembolism, central retinal artery occlusion, and central retinal vein occlusion were calculated and examined over time. The cumulative incidence was plotted and hazard ratios (HRs) of thromboembolic events were calculated, adjusting for independent risk factors of thromboembolism. Results Patients with GCA and overlapping disease exhibited higher IRRs for all thromboembolic events compared to patients with OA. Patients with GCA had a higher risk of developing DVT and retinal vascular occlusions than those with overlapping disease (HR: 2.01, 95% confidence interval [CI]: 1.35-2.99, p < 0.001; HR: 2.37, 95% CI: 1.23-4.53, p = 0.009, respectively) or PMR alone (HR: 1.89, 95% CI: 1.50-2.41, p < 0.001; HR: 4.68, 95% CI: 3.10-7.07, p < 0.001, respectively). Patients with GCA had a higher risk of developing PE than those with PMR (HR: 1.55, 95% CI: 1.1-2.18, p = 0.01). Conclusion The risk of thromboembolic events differs between GCA, PMR, and overlapping diseases. Our findings may help predict the risk of thromboembolic events based on disease phenotype.
引用
收藏
页码:665 / 675
页数:11
相关论文
共 50 条
  • [21] Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
    Elfishawi, Mohanad
    Kaymakci, Mahmut
    Achenbach, Sara
    Crowson, Cynthia
    Kermani, Tanaz
    Weyand, Cornelia M.
    Koster, Matthew
    Warrington, Kenneth
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4765 - 4767
  • [22] Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study
    Raheel, Shafay
    Crowson, Cynthia S.
    Matteson, Eric L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [23] The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study
    Avina-Zubieta, J. Antonio
    Bhole, Vidula M.
    Amiri, Neda
    Sayre, Eric C.
    Choi, Hyon K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) : 148 - 154
  • [24] Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis
    Ungprasert, Patompong
    Sanguankeo, Anawin
    Upala, Sikarin
    Knight, Eric L.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 44 (03) : 366 - 370
  • [25] Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: A retrospective cohort study
    Moreel, Lien
    Betrains, Albrecht
    Boeckxstaens, Lennert
    Molenberghs, Geert
    Van Laere, Koen
    De Langhe, Ellen
    Vanderschueren, Steven
    Blockmans, Daniel
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 68
  • [26] Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study
    Brault, Clement
    Riis, Anders H.
    Mor, Anil
    Duhaut, Pierre
    Thomsen, Reimar W.
    [J]. CLINICAL EPIDEMIOLOGY, 2018, 10 : 1533 - 1543
  • [27] Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population
    Combe, B
    Sany, J
    Le Quellec, A
    Clot, J
    Eliaou, JF
    [J]. JOURNAL OF RHEUMATOLOGY, 1998, 25 (01) : 94 - 98
  • [28] Risk of arterial and venous thromboembolism in patients with atrial fibrillation or flutter: A nationwide population-based cohort study
    Sundboll, Jens
    Hovath-Puho, Erzsebet
    Adelborg, Kasper
    Ording, Anne
    Schmidt, Morten
    Botker, Hans Erik
    Sorensen, Henrik Toft
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 241 : 182 - 187
  • [29] Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica - a prospective cohort study
    Burg, Lara C.
    Karakostas, Pantelis
    Behning, Charlotte
    Brossart, Peter
    Kermani, Tanaz A.
    Schaefer, Valentin S.
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2023, 15
  • [30] Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review
    Liozon, Eric
    Parreau, Simon
    Filloux, Matthieu
    Dumonteil, Stephanie
    Gondran, Guillaume
    Bezanahary, Holy
    Ly, K. H.
    Fauchais, Anne Laure
    [J]. AUTOIMMUNITY REVIEWS, 2021, 20 (02)